Nuformix PLC Posting of Annual Report and Notice of AGM (2884G)
July 23 2021 - 8:35AM
UK Regulatory
TIDMNFX
RNS Number : 2884G
Nuformix PLC
23 July 2021
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of AGM
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that its Annual Report and Accounts for the
year ended 31 March 2021 and Notice of Annual General Meeting
("AGM") will be posted to shareholders later today and will be
available in full to download from the Company's website
(www.nuformix.com) shortly.
In accordance with the Listing Rule 9.6.1, a copy of these
documents has been uploaded to National Storage Mechanism and will
shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The AGM will be held at Orega, 70 Gracechurch Street, London,
EC3V 0HR on Tuesday, 24 August 2021 at 10.00am.
Shareholders should read the Notice of AGM for further details
of arrangements for attendance at the AGM and voting.
Enquiries:
Nuformix plc +44 (0)1223 627222
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0)203 328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR
Anna Dunphy / Paul McManus / Kiki +44 (0)207 933 8780
Zaccagnini nuformix@walbrookpr.com
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFIFIADAIVFIL
(END) Dow Jones Newswires
July 23, 2021 08:35 ET (12:35 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024